HAGHL: A Potential Drug Target Or Biomarker for Xenobiotics (G84264)

Target Name: HAGHL

NCBI ID: G84264

HAGHL

HAGHL: A Potential Drug Target Or Biomarker for Xenobiotics

HAGHL (Hydroxyacylglutathione hydrolase like, transcript variant 2) is a gene that encodes a protein known as HAGHL, which is a key enzyme in the detoxification of xenobiotics, such as drugs and other harmful substances. The encoded protein has been shown to play a crucial role in the elimination of xenobiotics from the body and is, therefore, a potential drug target or biomarker.

The HAGHL enzyme is a member of the cytoplasmic hydrolase family 4 (CHAPS) and is located on chromosome 11p16.2. It is a 16kDa protein that is expressed in various tissues and organs, including the liver, kidney, and heart. The HAGHL enzyme is responsible for the detoxification of xenobiotics by breaking down the bond between the xenobiotics and the cytosol of the cell.

The detoxification of xenobiotics is a critical process that is essential for maintaining the health and integrity of the body. Many xenobiotics, such as drugs, can be harmful to the body and cause damage over time. The HAGHL enzyme helps to eliminate these harmful substances from the body by breaking down the bonds between the xenobiotics and the cytosol of the cell.

HAGHL has been shown to play a crucial role in the detoxification of a wide range of xenobiotics, including drugs such as chemotherapy drugs, benzodiazepines, and pesticides. Studies have shown that the HAGHL enzyme is involved in the metabolism of these drugs and that its activity can be inhibited by these substances.

In addition to its role in drug metabolism, HAGHL has also been shown to play a role in the detoxification of other harmful substances, such as environmental toxins and radiation. The HAGHL enzyme is involved in the metabolism of these substances and is, therefore, a potential biomarker for their detoxification.

The potential use of HAGHL as a drug target or biomarker is an exciting area of research that has the potential to lead to the development of new treatments for a wide range of diseases. By inhibiting the activity of the HAGHL enzyme, researchers may be able to develop new drugs or other treatments that can specifically target this enzyme and enhance the detoxification of harmful substances from the body.

In conclusion, HAGHL (Hydroxyacylglutathione hydrolase like, transcript variant 2) is a gene that encodes a protein that plays a crucial role in the detoxification of xenobiotics from the body. The encoded protein is a potential drug target or biomarker and has the potential to lead to the development of new treatments for a wide range of diseases. Further research is needed to fully understand the role of HAGHL in the detoxification of xenobiotics and to explore its potential as a drug target or biomarker.

Protein Name: Hydroxyacylglutathione Hydrolase Like

Functions: Hydrolase acting on ester bonds

The "HAGHL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HAGHL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets